glp-1 alzheimer's trial glp 1 trials near me Disappointing Results in Trial: Underscores Promise (and Limits) of Single-Agent Approaches Experts propose 10-year testing – GLP-1s for Alzheimer's: Novo Nordisk

The Phase 2 Numbers Amgen reported topline Phase 2 results in November 2025 and presented detailed data at the American Diabetes Association meeting in June 2025

Common reported effects in clinical use include mild injection site reactions with subcutaneous administration, occasional digestive changes when taken orally, and rare reports of fatigue or dizziness

Investigating How GLP-1 May Contribute to Hair Loss Though not a direct side effect, a few mechanisms might explain how GLP-1 medications could indirectly contribute to hair loss

Combining IGF-1R localization with other protein biomarkers, notably markers of replication stress [132], could enrich the patient population selected for IGF-1R targeted therapeutics

Most patients begin to notice changes in body composition, energy, or recovery within 46 weeks, though optimal results are typically seen after 812 weeks of consistent use, alongside healthy lifestyle habits